Breaking News
Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research
Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic medicine, and InnDura Therapeutics, a newly formed company advancing Natural Killer (NK) cell research, have announced a new collaboration to develop and execute product development, regulatory, and chemistry, manufacturing and control (CMC) strategies to progress InnDura’s lead program to the clinic.
InnDura’s technology stems from original research and related discoveries under an exclusive license from the Dana-Farber Cancer Institute and the Massachusetts Institute of Technology (MIT) that focuses on EVE16 engineering of NK cells to provide enhanced cancer cell killing with greatly reduced cellular exhaustion and fratricide. The EVE16 technology can also be applied to T cells and other forms of cell therapy. Landmark Bio will serve as InnDura’s strategic partner in the research, development and manufacturing of their pipeline products.
“Working with Landmark Bio as our strategic partner saves us the time, resources and capital of building out CMC development and manufacturing capabilities ourselves, so we can focus all our efforts on creating and advancing safer, more effective cancer treatments for patients,” said John Beadle, M.D., MBA, chief executive officer (CEO) of InnDura Therapeutics. “Landmark Bio’s cell and gene therapy development, manufacturing expertise and state-of-the-art facilities are perfect for InnDura’s needs and we look forward to shaping our strategies together as our progress continues.”
“We are thrilled to partner with InnDura to translate their promising research into life-saving medicines,” said Ran Zheng, CEO of Landmark Bio. “This partnership is a great example of why Landmark Bio exists. In collaborating with innovators like InnDura, we can bring more advanced therapies to patients faster.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more